The study by Gillet et al. (2012), which included 80 serous ovarian cancer patients treated with carboplatin and paclitaxel, found S100A10 to be one of the 11 signature genes whose expression is involved in multidrug resistance [100]. Here, S100A10 is linked to ovarian serous adenocarcinoma.